19 results about "Interleukin 15" patented technology

The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.

The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

The invention provides a novel recombinant orf virus, the recombinant orf virus expresses interleukin 15, the recombinant orf virus is an ORFV (Open Reading Frame Virus) ORFs 005-008 gene deleted strain (marked as ORFV delta), and the IL15 gene expressed by the recombinant orf virus is one of a mouse source, a human source, a cat source or a dog source. According to the invention, an ORFV oncolytic virus is used as a carrier to develop a tumor immunotherapy drug ORFVdelta-IL15 expressing IL15, and the IL15 is expressed in tumor cells by using the characteristics of virus infection, so that the activation of NK cells and T cells in a tumor microenvironment is promoted while the tumor cells are cracked, and the anti-tumor effect of the oncolytic virus is enhanced. The invention provides a new strategy for tumor treatment.

Provided in the present application are an IL-15 mutant polypeptide, and a preparation method therefor and the use thereof. Further provided are a nucleic acid encoding the IL-15 mutant polypeptide, a vector containing the nucleic acid, and a host cell.

The present invention provides interleukin 15 (IL-15) variants comprising amino acid substitutions for improved homogeneity as well as conjugates and fusion proteins comprising such IL-15 variants. Further, nucleic acids, vectors and host cells for expression of such IL-15 variants as well as pharmaceutical composition comprising such IL-15 variants are provided.

Provided is a cytokine combination useful for treating a tumor and / or preventing recurrence or metastasis of the tumor. The cytokine combination with at least three cytokines selected from the following groups: interleukin 12 (IL12) or a functional variant thereof, granulocyte-macrophage colony-stimulating factor (GMCSF) or a functional variant thereof, FMS-like tyrosine kinase 3 ligand (FLT3L) or a functional variant thereof, interleukin 2 (IL2) or a functional variant thereof, interleukin 15 (IL15) or a functional variant thereof, interleukin 21 (IL21) or a functional variant thereof, and interleukin 7 (IL7) or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and / or preventing recurrence or metastasis of the tumor.

The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administering such agonistic IL-15 complexes.

The invention provides construction, preparation and application of a universal double-target BCMA (bovine serum albumin) / CD19-CAR-DNT (Chimeric Antigen Receptor-DNT) cell with enhanced functions. Specifically, the invention provides a chimeric antigen receptor construct of double-target BCMA / CD19, a membrane binding interleukin 15 (mbIL15) is fused at the C terminal of a bispecific CAR targeting BCMA and CD19 through a self-cleavage peptide, and the CAR construct is introduced into a DNT cell, so that a universal double-target BCMA / CD19-CAR-DNT cell with enhanced functions is obtained. The BCMA / CD19-CAR-DNT cell disclosed by the invention is targeted to BCMA and CD19 at the same time, and has stronger and more lasting cell killing activity, so that a new therapy is provided for BCMA and / or CD19 mediated diseases.

The present invention addresses the problem of providing an immune cell induced from an iPS cell, which imparts a phenotype that facilitates local migration and infiltration into a solid tumor and proliferation and survival of the immune cell in the solid tumor. [Solution] A cell which is an immune cell induced from an iPS cell and which expresses interleukin 15 and a cell surface molecule that is reactive with a tumor-associated antigen. And a cell which is an immune cell induced from an iPS cell and which expresses a cell surface molecule that is reactive with a tumor-associated antigen and interleukin 12, interleukin 18, or interleukin 21.

The present invention pertains to cell culture protocols and particularly provides a method for obtaining Invariant Natural Killer T (iNKT) cells. The method according to the present invention particularly comprises culturing peripheral blood mononuclear cells (PBMC) in a culture medium comprising alpha-Galactosylceramide (alpha-GalCer) and Interleukin 15 (IL-15). The present invention allows for the specific expansion of CD4V iNKT which have a particular interest in the prevention of graft versus host disease in the context of hematopoietic stem cell transplantation.

The present invention provides novel fusion proteins of interleukin 15, as well as prodrugs, compositions, and methods of preparation thereof, useful for the treatment of various diseases and disorders, such as hyperplasia, solid tumors, or hematopoietic malignancies.

Provided are an engineered immune cell expressing CXCL10 and IL15 and the use thereof. The immune cell can further express a chimeric antigen receptor or a T cell receptor. The engineered immune cell can enhance the recruitment and accumulation of immune cells, enhance the killing efficiency of immune cells on target cells, and enhance the treatment effect of immune cells on tumors, such as solid tumors.

The invention discloses an adeno-associated virus AAV vector. The adeno-associated virus AAV vector comprises a cytokine gene, the cell factor is selected from any one or more than two of the following components: human interleukin 2 (IL2), human interleukin 3 (IL3), human interleukin 6 (IL6), human interleukin 15 (IL15), human thrombopoietin (THPO), human stem cell factor (SCF) and human granulocyte-macrophage colony stimulating factor (GM-CSF). The invention also discloses an AAV vector combination comprising any two or more than three AAV vectors mentioned above. The invention also discloses an application of the AAV vector and a combination of the AAV vector in construction of immune system humanized non-human animals. The invention further discloses a method for constructing the immune system humanized non-human animal.

The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and / or survival of NK cells.

The present invention relates to a biopharmaceutical material and application of co-expressed porcine interleukin 15, 21 and 23, and relates to the field of biotechnology. The present invention provides a fusion protein comprising porcine interleukin 15, porcine interleukin 21 and porcine interleukin 23, consisting of an amino acid sequence as shown in SEQ ID NO: 1. A nucleic acid molecule encoding the fusion protein. A biopharmaceutical material comprising an expression cassette, a recombinant vector, a transfected cell, a recombinant microorganism, a culture product of the transgenic cell line or a fermentation product of the recombinant microorganism having the nucleic acid molecule. The present invention obtains a fusion protein by genetic recombination and fusing porcine interleukin 15, 21 and 23 genes, connecting them to a eukaryotic expression platform, and finding that the fusedly expressed IL-15, 21 and 23 have good biological effects of significantly enhancing the mucosal immune barrier function of animals, enhancing their systemic immunity level and anti-bacterial infection ability, and promoting the growth and development of animals.

The present disclosure provides methods and artificial expression constructs for improving the persistence or function of immune cells. In particular, the methods or artificial expression constructs include a mutant interleukin 15 (IL-15) transgene controlled by a constitutive or inducible promoter to enhance the function of immune cells. The mutant IL-15 is modified to concentrate signaling in a cell expressing IL-15R [alpha] and / or a signaling complex comprising IL-15R [alpha]. More specifically, the present disclosure provides methods and artificial expression constructs for enhancing immune cell function by enhancing immune cell proliferation, reducing antigen independent gamma interferon (IFN gamma) release, and inhibiting tumor growth and uncontrolled immune cell proliferation.

The present invention provides novel fusion proteins of interleukin 15, as well as prodrugs, compositions, and methods of preparation thereof, useful for the treatment of various diseases and disorders, such as hyperplasia, solid tumors, or hematopoietic malignancies.